Connect Biopharma Holdings
CNTB
29 hedge funds and large institutions have $23.9M invested in Connect Biopharma Holdings in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
17,033% more call options, than puts
Call options by funds: $514K | Put options by funds: $3K
876% more capital invested
Capital invested by funds: $2.45M → $23.9M (+$21.4M)
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
81% more funds holding
Funds holding: 16 → 29 (+13)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
12.23% more ownership
Funds ownership: 2.91% → 15.14% (+12%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$10.2M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$2.63M |
| 3 |
PA
Perceptive Advisors
New York
|
+$1.69M |
| 4 |
DMKJ
David M. Knott Jr
|
+$427K |
| 5 |
RB
Richmond Brothers
Jackson,
Michigan
|
+$370K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.83M |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$35.1K |
| 3 |
Renaissance Technologies
New York
|
-$32.2K |
| 4 |
Citigroup
New York
|
-$6.24K |
| 5 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$627 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
RhumbLine Advisers
Boston,
Massachusetts
| $2.2K | – | – | – |
|
27
JP Morgan Chase
New York
| $341 | – | – | – |
|
28
Simplex Trading
Chicago,
Illinois
| $276 | +$209 | +98 | New |
|
|
SS
29
SBI Securities
Tokyo,
Japan
| $17 | -$2 | -1 | -14% |
|
|
XT
30
XTX Topco
George Town,
Cayman Islands
| – | -$35.1K | -23,724 | Closed |
|
|
31
Citigroup
New York
| – | -$6.24K | -4,214 | Closed |
|
CNTB Hedge Fund Activity: Q4 2025 in Review
29 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q4 2025, worth a combined $23.9M — up 876% from $2.45M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CNTB positions and 2 closed out — a net gain of 13 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $10.2M. The largest seller was BML Capital Management, cutting an estimated $1.83M.
- 29 institutional investors held Connect Biopharma Holdings (CNTB) as of Q4 2025, up from 16 in Q3 2025.
- Funds reported $23.9M of Connect Biopharma Holdings stock for Q4 2025, up 876% quarter-over-quarter.
- 15 funds opened new Connect Biopharma Holdings positions in Q4 2025 and 2 closed out, a net change of +13 holders.
- The largest Connect Biopharma Holdings buyer in Q4 2025 was Ikarian Capital, an estimated $10.2M added.
- The largest Connect Biopharma Holdings seller in Q4 2025 was BML Capital Management, an estimated $1.83M sold.
Based on aggregated 13F filings for Q4 2025.